Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENT
CUSIPN/A
Phone650-641-2100
Debt
Debt-to-Equity RatioN/A
Current Ratio8.99
Quick Ratio8.39
Price-To-Earnings
Trailing P/E Ratio-60.58
Forward P/E Ratio-53.85
P/E GrowthN/A
Sales & Book Value
Annual Sales$96.30 million
Price / Sales10.62
Cash FlowN/A
Price / CashN/A
Book Value$3.98 per share
Price / Book8.52
Profitability
EPS (Most Recent Fiscal Year)($0.56)
Net Income$-16,360,000.00
Net Margins-15.73%
Return on Equity-13.67%
Return on Assets-12.06%
Miscellaneous
Employees327
Outstanding Shares30,140,000
Market Cap$1,027.63
Intersect ENT (NASDAQ:XENT) Frequently Asked Questions
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT Inc (NASDAQ:XENT) released its earnings results on Tuesday, May, 1st. The medical equipment provider reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. The medical equipment provider earned $24.70 million during the quarter, compared to analyst estimates of $23.66 million. Intersect ENT had a negative net margin of 15.73% and a negative return on equity of 13.67%. The firm's revenue for the quarter was up 20.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.23) earnings per share. View Intersect ENT's Earnings History.
When is Intersect ENT's next earnings date?
What price target have analysts set for XENT?
9 brokerages have issued 1-year price targets for Intersect ENT's shares. Their predictions range from $31.00 to $48.00. On average, they anticipate Intersect ENT's share price to reach $37.5714 in the next year. This suggests a possible upside of 10.7% from the stock's current price. View Analyst Ratings for Intersect ENT.
What is the consensus analysts' recommendation for Intersect ENT?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. Canaccord Genuity analysts commented, "We reiterate our BUY rating on XENT and view ongoing share weakness as a buying opportunity. Specifically, shares are down ~9% intraday following the release of preliminary CMS guidelines that deny XENT’s request for a standalone J-code for Sinuva. The decision was disclosed in the CMS preliminary agenda for the upcoming Public Meeting for Drugs, Biological, and Radiopharmaceuticals held on May 15, 2018 (link). In the preliminary guideline CMS denies XENT’s request for a product-specific J-code and instead assigns Sinuva to an old and soon to be defunct (as of Jan 1, 2019) Category 3 CPT code – 0406T. Our conversation with management suggests the decision in the preliminary guidelines was likely an oversight on the part of CMS and something that will likely be addressed when the topic presented at the meeting on May 15." (5/7/2018)
- 2. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (5/5/2018)
- 3. Northland Securities analysts commented, "We are raising our FY18 and FY19 numbers, in part due to elevated expectations on SINUVA. In our view, this story of marginal beats and managing Street expectations" is not enough to elevate the stock from its current 10x sales multiple." (5/2/2018)
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Nevro (NVRO), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY) and OraSure Technologies (OSUR).
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Ms. Lisa D. Earnhardt, Chief Exec. Officer, Pres and Director (Age 48)
- Ms. Jeryl L. Hilleman M.B.A, Chief Financial Officer (Age 60)
- Mr. Richard E. Kaufman, Chief Operating Officer (Age 56)
- Mr. David A. Lehman, Gen. Counsel & Sec. (Age 57)
- Ms. Gwen R. Carscadden, Chief People Officer (Age 57)
Has Intersect ENT been receiving favorable news coverage?
Press coverage about XENT stock has been trending positive on Saturday, according to Accern. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intersect ENT earned a media sentiment score of 0.26 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 44.75 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Intersect ENT's major shareholders?
Intersect ENT's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.15%), Boston Advisors LLC (0.10%), Xact Kapitalforvaltning AB (0.02%) and Campbell & CO Investment Adviser LLC (0.02%). Company insiders that own Intersect ENT stock include Amy Wolbeck, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, James Stambaugh, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.
Which major investors are buying Intersect ENT stock?
XENT stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Boston Advisors LLC, Xact Kapitalforvaltning AB and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Intersect ENT.
How do I buy shares of Intersect ENT?
Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of XENT stock can currently be purchased for approximately $33.9250.
How big of a company is Intersect ENT?
Intersect ENT has a market capitalization of $1.03 billion and generates $96.30 million in revenue each year. The medical equipment provider earns $-16,360,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Intersect ENT employs 327 workers across the globe.
How can I contact Intersect ENT?
Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]
MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
